ARCHIVES

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”

September 3, 1976

FTC Report Disagrees With Key Provision Of Biologics Bill Backed By Companies

June 12, 2009

Garb’s Questions, Answers About Cancer Program

December 12, 1980

FDA Faces Severe Regulatory, Scientific Needs, Report Finds.

February 1, 2008

Seventeen of 23 CHOPs Approved For Implementation

July 16, 1982

NCI’s Chabner Cautions Against 3-Hour Taxol Infusion, May Lower Response Rate

October 22, 1993